ORLANDO, Fla., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announces that William Mitchell, MD, PhD, Professor of Pathology, Microbiology & Immunology at Vanderbilt University, will review data on January 30, 2018 at the Keystone Symposia Conference on Emerging Technologies in Vaccine Discovery and Development evidencing the activity of Ampligen® (rintatolimod) in enabling nasally-administered seasonal flu vaccines to confer wide cross-reactivity/protection against influenza viruses, even against those they were not designed to protect. The immune-stimulant properties of Ampligen® as a restricted TLR3 agonist in nasal mucosa were observed in animal models and human subjects.

Dr. Mitchell also serves as the independent Chairman of the Board of Hemispherx.

The conference takes place at the Keystone Symposia on Molecular and Cellular Biology, Fairmont Banff Springs, Banff, Alberta, Canada, January 28-February 1, 2018.

Title: Evidence for a Restricted TLR Agonist, Rintatolimod, in the Induction of Cross Strain/Clade Influenza Protective Responses

Date: Tuesday, January 30, 2018 Time: 7:30 PM MST

A bout Hemispherx Biopharma Hemispherx Biopharma, Inc., is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life-threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials.

Cautionary StatementSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  Any forward-looking statements set forth in this press release speak only as of the date of this press release.  We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

ContactHemispherx Biopharma Phone Number: 800-778-4042 Email: IR@hemispherx.net 

Primary Logo